LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION

被引：0
|
作者：
Ascher-Svanum, Haya [1 ]
Novick, Diego [2 ]
Haro, Josep M. [3 ]
Bertsch, Jordan [3 ]
McDonnell, David [1 ]
Detke, Holland [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Windlesham, Surrey, England
[3] Univ Barcelona, CIBERSAM, Parc Sanitari St Joan Deu, Barcelona, Spain
来源：
SCHIZOPHRENIA RESEARCH | 2012年 / 136卷
关键词：
D O I：
10.1016/S0920-9964(12)70521-2
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
207
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [1] Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
    Ascher-Svanum, Haya
    Novick, Diego
    Maria Haro, Josep
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1125 - 1131
  • [2] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [3] OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, P. M.
    Choukour, M.
    Watson, Susan B.
    Brunner, E.
    Ascher-Svanum, H.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 300 - 300
  • [4] Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study
    Detke, H.
    Weiden, P. J.
    Lambert, T.
    Llorca, P. M.
    Choukour, M.
    Watson, S. B.
    Brunner, E.
    Ascher-Svanum, H.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S464 - S464
  • [5] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, D.
    Ascher-Svanum, H.
    Bertsch, J.
    Detke, H.
    Mcdonnell, D.
    Witte, M.
    Haro, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A288 - A289
  • [6] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, Diego
    Ascher-Svanum, Haya
    Bertsch, Jordan
    Detke, Holland C.
    McDonnell, David
    Maria Haro, Josep
    [J]. SCHIZOPHRENIA RESEARCH, 2012, 136 : S357 - S357
  • [7] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Peuskens, Joseph
    Porsdal, Vibeke
    Pecenak, Jan
    Handest, Peter
    D'yachkova, Yulia
    Brousil, Radim
    Deberdt, Walter
    [J]. BMC PSYCHIATRY, 2012, 12
  • [8] Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
    Joseph Peuskens
    Vibeke Porsdal
    Jan Pecenak
    Peter Handest
    Yulia D'yachkova
    Radim Brousil
    Walter Deberdt
    [J]. BMC Psychiatry, 12
  • [9] Olanzapine Long-Acting Injection A Review of its Use in the Treatment of Schizophrenia
    Frampton, James E.
    [J]. DRUGS, 2010, 70 (17) : 2289 - 2313
  • [10] Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
    Detke, H.
    McDonnell, D.
    Kane, J.
    Naber, D.
    Sethuraman, G.
    Lin, D.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S393 - S394
12345